Juvenile Idiopathic Arthritis
2 original drugsJuvenile Idiopathic Arthritis has 2 FDA-approved novel treatments, led by AbbVie across 5 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.
Juvenile Idiopathic Arthritis Market Leaders
Companies with the most FDA-approved novel Juvenile Idiopathic Arthritis drugs.
Phase 3 Readouts Pro
2 active Phase 3 trials with confidence-graded completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Juvenile Idiopathic Arthritis Treatments by Mechanism
Top 6 mechanisms across 23 industry trials with a known mechanism of action.
MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.
Juvenile Idiopathic Arthritis Clinical Pipeline by Phase
46 industry-sponsored trials across 19 sponsors
Precision Medicine Biomarkers
All biomarkers →Biomarkers used for patient selection in Juvenile Idiopathic Arthritis
Novel Juvenile Idiopathic Arthritis Drugs by Company (New molecular entities)
2 companies have an FDA-approved novel drug for Juvenile Idiopathic Arthritis.
Reformulations (2 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
Juvenile Idiopathic Arthritis Drug Targets
Molecular targets of approved and investigational Juvenile Idiopathic Arthritis drugs — 5 targets tracked.
Biosimilars (10 BLA approved) Click to expand
Biosimilars are biological products highly similar to FDA-approved reference biologics with no clinically meaningful differences in safety, purity, or potency.
Generic Drugs (3 ANDA approved) Click to expand
Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs